Drug Trial Radar · NCT07858734
Postsurgical Analgesia After Unilateral Bunionectomy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Apr 15, 2027
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- AmacaThera Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of two doses of AMT-143 in participants after unilateral bunionectomy.
Conditions
- Bunionectomy
- Bunion
Interventions
AMT-143Drug
Group 1 will receive AMT-143 containing 354 mg ropivacaine.
AMT-143Drug
Group 2 will receive AMT-143 containing 707 mg ropivacaine.
Saline (NaCl 0,9 %) (placebo)Other
Group 3 will receive 2.00 mL Placebo \[sodium chloride (NaCl) 0.9%\].
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of AMT-143Time frame: From surgery to Day 28 follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Diex Reserche
Sherbrooke, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.